- Featured Product
- KD/KO Validated
EZH2 Polyclonal antibody
EZH2 Polyclonal Antibody for FC, IF/ICC, IP, WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat and More (2)
Applications
FC, IF/ICC, IP, WB, ELISA and More (3)
Conjugate
Unconjugated
验证数据展示
经过测试的应用
| Positive WB detected in | DU 145 cells, HEK-293 cells, mouse kidney tissue, NIH/3T3 cells, Raji cells, Jurkat cells, A431 cells, HepG2 cells, rat kidney tissue, C6 cells |
| Positive IP detected in | HepG2 cells |
| Positive IF detected in | HepG2 cells |
| Positive FC detected in | HepG2 cells |
This antibody is not recommended for use in IHC.
Planning an IF experiment? We recommend our CoraLite® Plus 488, CoraLite®555 and CoraLite® Plus 647 conjugated versions of this antibody.
推荐稀释比
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunofluorescence (IF) | IF : 1:20-1:200 |
| Flow Cytometry (FC) | FC : 0.20 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
21800-1-AP targets EZH2 in WB, RIP, IP, IF, FC, CoIP, ChIP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Applications | FC, IF/ICC, IP, WB, ELISA |
| Cited Applications | CHIP, CoIP, IF, IP, RIP, WB |
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, rat, sheep, pig |
| Immunogen | EZH2 fusion protein Ag16789 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Full Name | enhancer of zeste homolog 2 (Drosophila) |
| Synonyms | Enhancer of zeste homolog 2, ENX 1, ENX-1, EZH1, EZH2, KMT6, Lysine N methyltransferase 6 |
| Calculated Molecular Weight | 751 aa, 86 kDa |
| Observed Molecular Weight | 90-102 kDa |
| GenBank Accession Number | BC010858 |
| Gene Symbol | EZH2 |
| Gene ID (NCBI) | 2146 |
| RRID | AB_10858790 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q15910 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
EZH2 (enhancer of zeste homologue 2, also known as KMT6) is a member of Polycomb group (PcG) family and encodes a histone methyl transferase that has an essential role in promoting histone H3 lysine 27 trimethylation (H3K27me3) and epigenetic gene silencing. EZH2 is important for cell proliferation and inhibition of cell differentiation, and is implicated in cancer progression. Overexpression of EZH2 is a marker of advanced and metastatic disease in many solid tumors, including prostate and breast cancer. This antibody detected EZH2 protein as a single band with a molecular weight (MW) of 91-100 kDa in multiple cell lines. The phosphorylation may result in the higher molecular weight (calculated MW as 80-86 kDa). (20935635, 21367748)
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for EZH2 antibody 21800-1-AP | Download protocol |
| IF protocol for EZH2 antibody 21800-1-AP | Download protocol |
| IP protocol for EZH2 antibody 21800-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Nat Struct Mol Biol lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal. | ||
Cancer Res HBXIP and LSD1 Scaffolded by lncRNA Hotair Mediate Transcriptional Activation by c-Myc. | ||
Theranostics Histone H3K27 methyltransferase EZH2 regulates apoptotic and inflammatory responses in sepsis-induced AKI
| ||
Nat Commun CDYL suppresses epileptogenesis in mice through repression of axonal Nav1.6 sodium channel expression.
| ||
Clin Cancer Res Single-Cell Analyses Reveal Mechanisms of Cancer Stem Cell Maintenance and Epithelial-Mesenchymal Transition in Recurrent Bladder Cancer.
|
